Signal active
Organization
Contact Information
Overview
Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell-mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases. The eFGF-1 technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which debilitating and cause a significant amount of preventable blindness throughout the world.
Trefoil focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision. The company's mission is to improve human health and create new therapies using drugs developed with protein engineering.
The management team at Trefoil has more than 100 years of pharmaceutical development and commercialization experience. As an early-stage development company, Trefoil has been recognized by the biopharmaceutical funding community through the CONNECT Springboard business plan program award and the Southeast Biotechnology Early Company Competition.
About
Biotechnology, Health Care, Therapeutics
2014
1-10
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Trefoil Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Therapeutics sector. The company focuses on Biotechnology and has secured $7.2B in funding across 84 round(s). With a team of 1-10 employees, Trefoil Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Trefoil Therapeutics, raised $5.2M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
7
4
0
$85.8M
Details
3
Trefoil Therapeutics has raised a total of $85.8M in funding over 3 rounds.
Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
---|---|---|---|---|
2019 | Early Stage Venture | 28.0M | ||
2021 | Early Stage Venture | 28.0M | ||
2017 | Early Stage Venture | 5.2M |
Investors
Trefoil Therapeutics is funded by 23 investors.
Investor Name | Lead Investor | Funding Round | Partners |
---|---|---|---|
Aju IB Investment | - | FUNDING ROUND - Aju IB Investment | 5.2M |
ExSight Ventures | - | FUNDING ROUND - ExSight Ventures | 5.2M |
Trefoil Therapeutics | - | FUNDING ROUND - Trefoil Therapeutics | 5.2M |
InFocus Capital Partners | - | FUNDING ROUND - InFocus Capital Partners | 5.2M |
Recent Activity
There is no recent news or activity for this profile.